• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiplatelet Therapy After PCI: The Art and Science of De-Escalation.

作者信息

Storey Robert F

机构信息

Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, United Kingdom (R.F.S.).

National Institute for Health and Care Research Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom (R.F.S.).

出版信息

Circulation. 2024 Feb 20;149(8):601-604. doi: 10.1161/CIRCULATIONAHA.123.067767.

DOI:10.1161/CIRCULATIONAHA.123.067767
PMID:38377261
Abstract
摘要

相似文献

1
Antiplatelet Therapy After PCI: The Art and Science of De-Escalation.PCI术后的抗血小板治疗：降阶梯治疗的艺术与科学
Circulation. 2024 Feb 20;149(8):601-604. doi: 10.1161/CIRCULATIONAHA.123.067767.
2
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.比较血管内超声或血管造影指导下急性冠脉综合征患者药物洗脱支架植入术后 1 个月与 12 个月双联抗血小板治疗：前瞻性、多中心、随机、对照 IVUS-ACS 和 ULTIMATE-DAPT 试验的原理和设计。
Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20.
3
De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.经皮冠状动脉介入治疗的急性冠状动脉综合征患者从普拉格雷或替格瑞洛降级为氯吡格雷治疗：随机临床试验的最新荟萃分析
Am J Cardiovasc Drugs. 2022 May;22(3):287-298. doi: 10.1007/s40256-021-00504-7. Epub 2021 Oct 15.
4
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.基于真实世界数据的 CYP2C19 指导的抗血小板治疗在急性冠状动脉综合征和经皮冠状动脉介入治疗患者中的成本效益。
Pharmacogenomics J. 2020 Oct;20(5):724-735. doi: 10.1038/s41397-020-0162-5. Epub 2020 Feb 11.
5
Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.随机评估急性冠状动脉综合征患者接受药物涂层球囊治疗后 1 个月双联抗血小板治疗后 5 个月替格瑞洛单药治疗的疗效：RE-CAGEFREE II 试验原理和设计。
BMC Cardiovasc Disord. 2024 Jan 20;24(1):62. doi: 10.1186/s12872-024-03709-1.
6
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).在英国，综合评估不同双联抗血小板治疗 (DAPT) 和三联治疗 (TT) 方案处方患者的出血情况：三个基于人群的队列研究的研究方案，模拟“目标试验”（ADAPTT 研究）。
BMJ Open. 2019 Jun 4;9(6):e029388. doi: 10.1136/bmjopen-2019-029388.
7
Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.替格瑞洛单药治疗行经皮冠状动脉介入治疗的急性冠状动脉综合征患者的安全性和疗效：TWILIGHT 和 TICO 随机试验的个体患者数据荟萃分析。
Circulation. 2024 Feb 20;149(8):574-584. doi: 10.1161/CIRCULATIONAHA.123.067283. Epub 2023 Oct 23.
8
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.替格瑞洛转为氯吡格雷治疗急性心肌梗死患者：TALOS-AMI HBR 亚研究。
EuroIntervention. 2023 Dec 4;19(10):e832-e843. doi: 10.4244/EIJ-D-23-00427.
9
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.较高的中性粒细胞与淋巴细胞比值（NLR）增加了接受替格瑞洛双联抗血小板治疗的 ACS 患者发生血小板抑制不足和主要心血管缺血事件的风险。
Vascul Pharmacol. 2020 Sep;132:106765. doi: 10.1016/j.vph.2020.106765. Epub 2020 Jul 16.
10
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.接受复杂经皮冠状动脉介入治疗的患者在 1 个月双联抗血小板治疗后长期使用替格瑞洛单药治疗的影响：来自全球领导者试验的见解。
Eur Heart J. 2019 Aug 14;40(31):2595-2604. doi: 10.1093/eurheartj/ehz453.

引用本文的文献

1
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.急性冠状动脉综合征后替格瑞洛单药治疗：来自ULTIMATE-DAPT试验的经验教训。
Future Cardiol. 2024;20(11-12):591-593. doi: 10.1080/14796678.2024.2388472. Epub 2024 Aug 12.
2
Patient and Physician Perspectives on the Benefits and Risks of Antiplatelet Therapy for Acute Coronary Syndrome.患者与医生对急性冠状动脉综合征抗血小板治疗的获益与风险的看法
Cardiol Ther. 2024 Sep;13(3):631-643. doi: 10.1007/s40119-024-00372-7. Epub 2024 Jun 21.